Davidson Mayer B
Charles R. Drew University, Los Angeles, CA, USA.
Mellitus Health, Inc., Beverly Hills, CA, USA.
J Diabetes Sci Technol. 2024 Dec 23:19322968241306127. doi: 10.1177/19322968241306127.
Primary care clinicians (PCCs) manage 90% of patients with diabetes, 30% of whom require insulin with a substantial number poorly controlled because of the challenges that PCCs face (time constraints and lack of experience). The author has developed Federal Drug Administration cleared and Conformite Europeenne mark registered comprehensive computerized insulin dose adjustment algorithms (CIDAAs) to enable PCCs to significantly lower HbA1c levels in insulin-requiring patients. Reports sent to PCCs contain scatter plots of glucose readings, their organization into pre- and postprandial and before bedtime values, their analyses, and recommendations for insulin dose adjustments (if indicated) that the PCC can accept or modify. The glucose readings are provided to the CIDAAs for analysis at either in-person visits or remotely. The new doses accepted by PCCs serve as the basis for the subsequent report. Published studies evaluating this comprehensive CIDAA involved 104 poorly controlled patients taking insulin for greater than or equal to six months who were independently managed by PCCs. Over four to six months, initial HbA1c levels of 9.7% fell by 1.7%. Combining these results with 138 other better controlled patients in real-world situations, initial measured and estimated HbA1c levels of 8.3% fell by 0.7% in 6.4 months enabling PCCs to significantly improve glycemic control. Other advantages of PCCs utilizing these comprehensive CIDAAs are saving time for PCCs so that they can address non-diabetes issues and/or see other patients and ongoing PCC education in adjusting insulin doses by matching glucose patterns and dose-change recommendations with subsequent glycemic responses.
基层医疗临床医生(PCCs)负责管理90%的糖尿病患者,其中30%需要胰岛素治疗,由于PCCs面临的挑战(时间限制和经验不足),相当一部分患者血糖控制不佳。作者开发了经美国食品药品监督管理局批准并获得欧洲符合性认证标志注册的全面计算机化胰岛素剂量调整算法(CIDAAs),以使PCCs能够显著降低需要胰岛素治疗患者的糖化血红蛋白(HbA1c)水平。发送给PCCs的报告包含血糖读数的散点图、按餐前、餐后和睡前值进行的分类、分析以及胰岛素剂量调整建议(如适用),PCCs可以接受或修改这些建议。血糖读数会在面诊或远程就诊时提供给CIDAAs进行分析。PCCs接受的新剂量将作为后续报告的依据。评估这种全面CIDAAs的已发表研究涉及104名血糖控制不佳、使用胰岛素至少6个月且由PCCs独立管理的患者。在4至6个月的时间里,初始糖化血红蛋白水平9.7%下降了1.7%。将这些结果与现实世界中另外138名血糖控制较好的患者相结合,初始测量和估计的糖化血红蛋白水平8.3%在6.4个月内下降了0.7%,使PCCs能够显著改善血糖控制。PCCs使用这些全面CIDAAs的其他优势包括为PCCs节省时间,使其能够处理非糖尿病问题和/或看其他患者,以及通过将血糖模式和剂量变化建议与随后的血糖反应相匹配,对PCCs进行持续的胰岛素剂量调整教育。